Exelixis (EXEL) Q2 2026 Earnings Call Transcript

Exelixis reported Q2 2026 total revenues of $628.7M (+10.6% YoY) with cabozantinib net product revenues of $573.0M (+10.2% YoY); non-GAAP net income was $237.1M ($0.91/share). The company lowered FY2026 revenue guidance to $2.50B–$2.55B (down $50M at the midpoint) due to a slower neuroendocrine tumor NET sales ramp and reduced FY2026 R&D guidance midpoint by $50M (to $825M–$875M). Meanwhile, it maintained momentum on zanzalintinib: STELLAR-303 met the overall survival endpoint and FDA review timing for the CRC combination is set with a PDUFA date of Dec. 3, 2026; Exelixis also continued shareholder returns with a $311.6M Q2 repurchase (6.5M shares at ~$47.85).

Analysis

The near-term read is not “new growth story,” it is “cash engine with a longer bridge.” The core franchise is still doing the heavy lifting, but the guidance trim tells you the market’s next leg is less about revenue acceleration and more about whether management can keep converting a mature asset into buybacks while buying time for zanzalintinib. That usually supports the downside, but it also caps the multiple unless investors see a cleaner second franchise path.

The bigger second-order question is not the PDUFA itself, it is how much commercial value survives a potentially messy label. A broad launch in late-line CRC could re-rate the name, but a label that leaves too much ambiguity around subgroup interpretation or sequencing would make uptake more incremental than the market likely models. By contrast, the kidney program matters more structurally: a clean positive readout there would validate the platform beyond one tumor type and extend the duration of the bull case into 2027-2028 rather than just a binary launch pop.

Contrarian view: the market may be overreacting to slower NET growth as if it were a demand miss, when it may simply reflect a slower treatment cadence in a small population. The risk is that investors underwrite today’s commercial base and tomorrow’s pipeline as if both are equally de-risked; they are not. The thesis breaks if gross-to-net moves back up, if CRC labeling narrows materially, or if the second-half kidney readout disappoints, because then the stock is left looking like a buyback story with less pipeline convexity than advertised.

Key Decisions for Investors

• Initiate a small tactical long in EXEL only on post-earnings weakness; better entry is after the market has digested label-risk headlines than chasing pre-PDUFA strength. Use a tight stop if the stock loses the post-call support level and volume expands on downside.
• For 1-3 month expression, pair long EXEL vs short XBI to isolate company-specific catalyst risk from biotech beta. This is most attractive if implied volatility stays elevated into the Dec. 3 FDA date.
• If using options, prefer a Jan-2027 bull call spread in EXEL over outright stock into the CRC PDUFA and second-half kidney data window. Risk/reward is better if you want upside convexity without paying full-event premium.
• Watch NTRA as a secondary beneficiary of the MRD-driven CRC expansion thesis, but do not add until enrollment/screening cadence is independently confirmed. The setup is real, but the evidence is still too preliminary for a standalone trade.